Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideki Enokida

Showing results (41-50 of 177) with videos related to

Pageof 18
Sort By:
Cancer Science|April 2, 2020
Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinomaKazuki Kuroshima, Hirofumi Yoshino, Shunsuke Okamura, et al.
International Journal of Molecular Medicine|July 3, 2010
CpG hypermethylation of human four-and-a-half LIM domains 1 contributes to migration and invasion activity of human bladder cancerMitsugi Matsumoto, Kazumori Kawakami, Hideki Enokida, et al.
Cancer|September 1, 2005
WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinomaMasanori Kaneuchi, Masahiro Sasaki, Yuichiro Tanaka, et al.
International Journal of Oncology|April 4, 2019
Tumor‑suppressive microRNA‑223 targets WDR62 directly in bladder cancerSatoshi Sugita, Hirofumi Yoshino, Masaya Yonemori, et al.
International Journal of Cancer|February 26, 2011
miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinomaMasayuki Kano, Naohiko Seki, Naoko Kikkawa, et al.
Oncotarget|August 14, 2014
The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancerYusuke Goto, Satoko Kojima, Rika Nishikawa, et al.
Cancer Science|July 30, 2013
Tumor-suppressive microRNA-1291 directly regulates glucose transporter 1 in renal cell carcinomaTakeshi Yamasaki, Naohiko Seki, Hirofumi Yoshino, et al.
Molecular Oncology|May 10, 2020
Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylationHirofumi Yoshino, Hideki Enokida, Yoichi Osako, et al.
Plos One|May 8, 2020
Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistantMasafumi Tsuruda, Hirofumi Yoshino, Shunsuke Okamura, et al.
International Journal of Oncology|May 9, 2009
CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancerKatsuhisa Mori, Hideki Enokida, Ichiro Kagara, et al.
Pageof 18

Showing results (41-50 of 177) with videos related to

Sort By:
Pageof 18
Cancer Science|April 2, 2020
Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinomaKazuki Kuroshima, Hirofumi Yoshino, Shunsuke Okamura, et al.
International Journal of Molecular Medicine|July 3, 2010
CpG hypermethylation of human four-and-a-half LIM domains 1 contributes to migration and invasion activity of human bladder cancerMitsugi Matsumoto, Kazumori Kawakami, Hideki Enokida, et al.
Cancer|September 1, 2005
WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinomaMasanori Kaneuchi, Masahiro Sasaki, Yuichiro Tanaka, et al.
International Journal of Oncology|April 4, 2019
Tumor‑suppressive microRNA‑223 targets WDR62 directly in bladder cancerSatoshi Sugita, Hirofumi Yoshino, Masaya Yonemori, et al.
International Journal of Cancer|February 26, 2011
miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinomaMasayuki Kano, Naohiko Seki, Naoko Kikkawa, et al.
Oncotarget|August 14, 2014
The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancerYusuke Goto, Satoko Kojima, Rika Nishikawa, et al.
Cancer Science|July 30, 2013
Tumor-suppressive microRNA-1291 directly regulates glucose transporter 1 in renal cell carcinomaTakeshi Yamasaki, Naohiko Seki, Hirofumi Yoshino, et al.
Molecular Oncology|May 10, 2020
Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylationHirofumi Yoshino, Hideki Enokida, Yoichi Osako, et al.
Plos One|May 8, 2020
Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistantMasafumi Tsuruda, Hirofumi Yoshino, Shunsuke Okamura, et al.
International Journal of Oncology|May 9, 2009
CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancerKatsuhisa Mori, Hideki Enokida, Ichiro Kagara, et al.
Pageof 18